AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

Ceesay Abraham sold $87K of RAPP

Ceesay Abraham (Chief Executive Officer) sold 2,210 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $39.17 ($39.05–$41.05) across 3 trades on 2026-09-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ceesay Abraham
Published Sep 24, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Neutral
high confidence
Mentioned
$RAPP
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPNeutralLow
01

Why it matters

The disclosed sale is routine and modest; unlikely to affect valuation.

02

Market read

Primary disclosure of a small insider sell; low trading relevance.

03

What to watch

Potential upcoming clinical data releases could outweigh the sell signal.

Relevance 2/10Novelty 4/10Timing: filing date Sep 24 2026

Background

Form 4 filing discloses insider transactions; required by SEC for officers and directors.

Company-level read

Ticker impact

$RAPPNeutralHigh confidence
Context

CEO Ceesay Abraham sold 2,210 shares for $86,565 via a 10b5‑1 plan, reducing his stake to 456,767 shares.

Expected impact

Minimal short‑term dip or flat price action.

Evidence & confidence

The sale amount is small relative to total holdings and market cap; typical for routine 10b5‑1 execution.

Market effects

Sector

No sector-wide impact; biotech sector unchanged.

Regional

U.S. market only; no regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Insider sell could be a red flag if accompanied by other negative news.

Key entities

  • Company
    Rapport Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Person
    Ceesay Abraham

    Chief Executive Officer of Rapport Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com